Jamie Mullen

Jamie Mullen

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Psychiatry
AD Scientific Index ID: 4400868
-
person_outline Jamie Mullen's MOST POPULAR ARTICLES
1-) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder Journal of Clinical Psychiatry 66 (1), 111-121, 2005
2-) Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial European Neuropsychopharmacology 15 (5), 573-585, 2005
3-) Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania Journal of clinical psychopharmacology 24 (6), 599-606, 2004
4-) Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trialRS McIntyre, M Brecher, B Paulsson, K Huizar, J MullenEuropean Neuropsychopharmacology 15 (5), 573-585, 20053412005
5-) Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar maniaLN Yatham, B Paulsson, J Mullen, M VågeröJournal of clinical psychopharmacology 24 (6), 599-606, 20042442004